Pain management

Comprehensive testing to mitigate risks

The use of controlled substances to manage pain is widely accepted by healthcare professionals, but these prescriptions correlate with an increased risk for abuse and overdose. Because many patients on long-term controlled substance therapy struggle with addiction, objective measures are needed to identify recent use and evaluate for misuse.

Our patient-centric approach to controlled substance monitoring is backed by more than 150 years of medical knowledge and developed by an award-winning team of pain medicine, primary care, addiction experts, and laboratory scientists. Our tests align with the American Association for Clinical Chemistry Academy’s practice guidelines and provide clinicians with assistance to ensure patients who receive controlled substance therapy remain within regulatory parameters.

More information

Full-spectrum approach to pain management testing

  • Controlled substance monitoring
    • Specimen validity testing
    • Targeted mass spectrometry screening profiles
    • Select immunoassay screening
    • Confirmatory testing with quantification
    • Result interpretations
  • Pharmacogenomic testing
  • Therapeutic drug monitoring
  • Clinical research
  • Expert support and education 

Pain management testing services

Comprehensive monitoring

Key testing

*To better meet the needs of our clients, this profile is available with the quantification of presumptive positive results (Mayo ID: CSMPU) or without (Mayo ID: CSMHU) for the drug classes screened by immunoassay (i.e., barbiturates, cocaine, and THC).

**Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are direct biomarkers of ethanol and are detectable in urine for up to five days following alcohol consumption. EtG/EtS results should be interpreted in the context of all available clinical and behavioral information.

Routine monitoring

Key testing

Please note: If the limited immunoassay screen is positive in this profile (Mayo ID: CSMPU), confirmation with quantification of presumptive positives for barbiturates, cocaine and metabolites, and/or tetrahydrocannabinol metabolite will be performed at an additional charge. If the quantification of presumptive positive results is not required, refer to Controlled Substance Monitoring Hybrid Drug Profile, High-Resolution Mass Spectrometry, and Immunoassay Screen, Random, Urine (Mayo ID: CSMHU).

Targeted screening

Key testing



Fill out the form below and one of our specialists will be in touch.